drugset / Trial / NCT01093534

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534

Phase 4 Completed 547 enrolled Astellas Pharma Inc
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.

Timeline

Start
2010-01-19
Primary completion
2011-06-23
Completion
2011-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 5 mg Oral
Subject Solifenacin Small molecule 10 mg Oral

Indications